This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

8 Biotech Stocks to Watch

Stocks in this article: HITK CELG BIIB CRL ILMN TEVA WX DNDN

NEW YORK ( TheStreet) -- The markets were a mixed bag over the past month or so. The S&P 500 declined 2.8%, while the S&P 500 Biotechnology Index and the Nasdaq gained 3.3% and 4.1%, respectively. Industry analysts believe the recent selloff signals bargain-buying opportunities for investors as most of these stocks are trading at attractive discounts.

Despite challenges from the worldwide economic turmoil, the global biotech and pharmaceutical industry achieved profitability for the second consecutive year in 2010 with an acceleration in merger and acquisition activity. During the first quarter of 2011, the value of mergers and acquisitions in the biotech industry was more than $1 billion. Specifically, with cancer drugs costing the U.S. a whopping $30 billion each year, it is a lucrative sector for drug developers.

Based on latest quarterly results and according to analysts' recommendations, these eight biotech stocks have potential upsides ranging from 8% to 62%. On average, these stocks have buy recommendations of 65% and hold ratings of 29%, based on a Bloomberg consensus.

>> Keep the stock market at your fingertips with TheStreet's iPad app.

These stocks are listed in ascending order of upside potential.

1 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,416.85 +225.48 1.31%
S&P 500 2,021.25 +19.09 0.95%
NASDAQ 4,683.4070 +45.4130 0.98%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs